Premium
Aplastic Anemia Associated With Prolonged High‐Dose Trimethoprim‐Sulfadiazine Administration in Two Dogs
Author(s) -
Fox Leslie E.,
Ford Susan,
Alleman Arthur R.,
Harvey John W.,
Homer Bruce L.
Publication year - 1993
Publication title -
veterinary clinical pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 51
eISSN - 1939-165X
pISSN - 0275-6382
DOI - 10.1111/j.1939-165x.1993.tb00659.x
Subject(s) - sulfadiazine , medicine , trimethoprim , aplastic anemia , pneumonia , pyoderma , urinary system , sepsis , antibiotics , gastroenterology , dermatology , microbiology and biotechnology , bone marrow , biology
Trimethoprim‐sulfadiazine (TMP‐SDZ) (Tribressin tablets 120‐100 mg sulfadiazine, 20‐mg trimethoprim [Coopers Animal Health, Inc., A Pitman‐Moore Company, Mundelein, III.]) is a broad spectrum antibiotic combination effective in the treatment of bacterial pneumonia, urinary tract infections, pyoderma, meningitis, and prostatitis. 1 In clinical trials in puppies and adult dogs, TMP‐SDZ was considered safe at both the manufacturer's recommended dose (15 mg/kg, b.i.d., or 30 mg/kg, u.i.d., per os for < 14 days 2 ) and at 10 times that dose for 20 days. 3 Many infections, however, require prolonged high‐dose therapy for resolution. The following study describes two cases of aplastic anemia and sepsis associated with intermittent, chronic (17–25 days), high‐dose (25–30 mg/kg, b.i.d., per os) TMP‐SDZ therapy recommended for the treatment of pyoderma. 4–7